



Selected Papers in the 1st International Electronic Conference on Biomedicine (ECB 2021)

Guest Editors:

Prof. Dr. Shaker A. Mousa

Dr. Zong Sheng Guo

Dr. Veronique Baud

Prof. Dr. Ciro Isidoro

Dr. Jacek M. Kwiecien

Prof. Ujendra Kumar

Dr. David L. Bartlett

Dr. Allan Stensballe

Dr. Muhammad Hanif

Prof. Dr. Alexander M. Seifalian

Dr. Masaru Tanaka

Deadline for manuscript
submissions:

closed (31 December 2021)

Message from the Guest Editors

ECB 2021 will present the latest research related to all aspects of research on human health and disease, the discovery and characterisation of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products.

Topics of interest include but are not limited to: nanomedicine and precision medicine; nutraceuticals, nano nutraceuticals, and nano pharmaceuticals; cancer therapeutics; metal-based therapeutics in preclinical and clinical developments; oncolytic virus-mediated immunotherapy; neuroprotective therapies in spinal cord injury; exploring biomedicines in behavioral neurology and neuropsychiatry; nanomaterials and its application in biomedicine; translational biomarkers in clinical biomedicine and precision medicine; G-protein-coupled receptor family; microbiota, probiotics, and nutraceuticals.

Prof. Dr. Shaker Mousa

Dr. Zong Sheng Guo

Dr. Veronique Baud

Prof. Dr. Ciro Isidoro

Assoc. Pro Jacek M. Kwiecien

Dr. Ujendra Kumar

Dr. David L. Bartlett

Dr. Allan Stensballe

Dr. Muhammad Hanif

Prof. Dr. Alexander Seifalian

Dr. Masaru Tanaka

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI